Akouos, Inc.
(NASDAQ : AKUS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.06%196.280.0%$1637.73m
BIIBBiogen, Inc. 0.43%385.181.7%$1248.14m
SNSSSunesis Pharmaceuticals, Inc. 7.14%12.900.7%$901.76m
NVAXNovavax, Inc. -4.26%172.2279.8%$661.18m
AMGNAmgen, Inc. -1.32%237.591.3%$617.93m
BNTXBioNTech SE 0.09%214.390.0%$525.75m
VRTXVertex Pharmaceuticals, Inc. -0.75%186.951.9%$493.62m
GILDGilead Sciences, Inc. -1.55%66.181.0%$472.89m
REGNRegeneron Pharmaceuticals, Inc. -0.33%534.272.7%$373.82m
ILMNIllumina, Inc. -0.18%454.523.5%$358.31m
ALXNAlexion Pharmaceuticals, Inc. -0.43%179.202.0%$335.86m
OCGNOcugen, Inc. -2.29%6.390.0%$280.81m
EXASEXACT Sciences Corp. -1.23%125.3518.1%$188.43m
TXG10X Genomics, Inc. -1.80%195.190.0%$168.07m
IOVAIovance Biotherapeutics, Inc. -1.38%24.280.0%$167.80m

Company Profile

Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA.